Stockreport

Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates [Yahoo! Finance]

Relay Therapeutics, Inc.  (RLAY) 
PDF Presented interim data for RLY-2608 fulvestrant showing 11.4-month median PFS in 2L patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer Continued progress [Read more]